Post-marketing safety re-evaluation of placental peptide injection in China: a large-scale multicenter real-world study
The ADR rate was 0.03%, confirming the favorable safety profile of placental polypeptide injection. These findings support its safe clinical use and can inform future regulatory and policy decisions.
Authors
- Liguang Duan
- Binliang Tong
- Xiaoguang Liu (ORCID: https://orcid.org/0000-0002-0176-3101)
- Zhuo Zhang (ORCID: https://orcid.org/0000-0002-0515-6288)
- Yan Wen (ORCID: https://orcid.org/0000-0002-3962-5994)
- Chen Tian (ORCID: https://orcid.org/0000-0002-4508-8080)
- Jie Chen (ORCID: https://orcid.org/0000-0001-6505-5449)
- Hongyin Zhang (ORCID: https://orcid.org/0000-0001-9861-0568)
- Chunhua Zhou (ORCID: https://orcid.org/0000-0002-2926-2130)
- Feng‐Rong An
- Lingjiao Wang (ORCID: https://orcid.org/0009-0005-9661-3577)
Institutions
- Hebei Medical University (CN)
- Kunming Third People's Hospital (CN)
- First Affiliated Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-03-04
- DOI
- https://doi.org/10.3389/fphar.2025.1541005
- Citations
- 2
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 3.25